Human vaccine research in the European Union

11Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

Your institution provides access to this article.

Abstract

The use of vaccines is saving millions of lives every year across the globe, but a number of important diseases such as HIV/AIDS, malaria, TB and hepatitis C continue to frustrate attempts to produce effective vaccines against them. Confronting these challenges will require new approaches and increased research efforts by the scientific community. The Sixth Framework Programme (FP6; 2002-2006) of the European Commission (EC) has been an important catalyst in this direction by allocating a financial contribution of more than EUR 210 million to a wide variety of vaccine research activities, ranging from basic vaccinology, translational research to clinical application of vaccines. Taken together, around 581 research groups from 52 countries are participating in the vaccine activities of FP6. This impressive number signals a new spirit of collaborative research, which will facilitate the exploitation of the immense possibilities in modern vaccinology. © 2008 Elsevier Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Olesen, O. F., Lonnroth, A., & Mulligan, B. (2009, January 29). Human vaccine research in the European Union. Vaccine. https://doi.org/10.1016/j.vaccine.2008.11.064

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free